Stephen Boatwright, MD
Pain Medicine · Myrtle Beach, SCNPI 1538157334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Boston Scientific at 32.5% of the total. Reporting peaked in 2019 at $796 and has fallen 73.6% since, to $211 in 2025.
Across 163 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$976
- Collegium Pharmaceutical, Inc.$720
- Nevro Corp.$211
- Scilex Pharmaceuticals Inc.$135
- Forte Bio-pharma LLC$132
- Abbott$131
- plus $698 from 19 others
What the payments were for
- Food & beverage$2,98499%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 35 | $976 |
| Collegium Pharmaceutical, Inc. | 56 | $720 |
| Nevro Corp. | 10 | $211 |
| Scilex Pharmaceuticals Inc. | 8 | $135 |
| Forte Bio-pharma LLC | 7 | $132 |
| Abbott | 9 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $129 |
| Nalu Medical, Inc. | 3 | $69 |
| Redhill Biopharma Inc. | 3 | $56 |
| Curonix LLC | 2 | $47 |
| AstraZeneca | 3 | $44 |
| Biodelivery Sciences International, Inc. | 3 | $43 |
| SPR Therapeutics, Inc | 1 | $40 |
| Pfizer | 3 | $37 |
| Amgen | 3 | $35 |
| GRT US Holding, Inc. | 1 | $33 |
| Biotronik NRO, Inc. | 1 | $23 |
| Virtus Pharmaceuticals LLC | 1 | $22 |
| AbbVie | 1 | $22 |
| Medtronic | 1 | $20 |
| Vertex | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Valinor Pharma, LLC | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,002 in reported general payments places this provider in the 55th percentile of 92 pain medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 22 | $31,956 |
| Xtampza ErOxycodone Myristate | 46 | $23,351 |
| OxycontinOxycodone Hcl | 32 | $19,637 |
| MovantikNaloxegol Oxalate | 32 | $13,579 |
| LinzessLinaclotide | 15 | $10,922 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 353 | $10,819 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 355 | $8,859 |
| Buprenorphine | 35 | $8,092 |
| Hysingla ErHydrocodone Bitartrate | 13 | $7,827 |
| Oxycodone Hcl | 420 | $7,793 |
| Lidocaine | 37 | $2,827 |
| Gabapentin | 182 | $2,550 |
| Morphine Sulfate ErMorphine Sulfate | 96 | $2,038 |
| Naloxone Hcl | 26 | $1,425 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 25 | $1,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er | $720 | $55,30768 claims |
| Redhill Biopharma Inc.Movantik | $56 | $13,57932 claims |
| AbbVieLinzess | $22 | $10,92215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 pain medicine providers in South Carolina.
Other pain medicine in Myrtle Beach
- Farayi MbuvahMyrtle Beach$11K
- Phillip SmithGreenville$303K
- Richard KlineConway$104K
- Channing WilloughbyMurrells Inlet$82K
- Michael WarrickSumter$50K
- Daniel AtkinsonGreenville$36K
- Michael WardenFlorence$20K
- Andrew MendelsonCharleston$19K
- Sankeerth ChallagundlaColumbia$15K
- Kevin WalkerGreenville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.